Document Detail

Off-label use of rituximab in systemic lupus erythematosus: a systematic review.
MedLine Citation:
PMID:  20155295     Owner:  NLM     Status:  MEDLINE    
Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two significant RCTs have reported negative findings, reopening the debate on clinical benefit. This review of the available data suggests that rituximab induces B-cell depletion in 95% of patients, and a significant reduction in disease activity is achieved with a relatively good safety profile in patients with SLE.
Eleanor Murray; Martin Perry
Related Documents :
517385 - Head and neck manifestations of sle.
20090495 - Lupus miliaris disseminatus faciei of the eyelids: report of two cases.
7874925 - Linkage analysis of malignancy-associated sarcoidosis.
19629625 - Subarachnoid hemorrhage in systemic lupus erythematosus in japan: two case reports and ...
9152695 - Traumatic radial head dislocation in children--a missed injury.
19355285 - Realities of publishing in a journal: why should you submit, what should you submit, an...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-02-13
Journal Detail:
Title:  Clinical rheumatology     Volume:  29     ISSN:  1434-9949     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-05-31     Completed Date:  2010-10-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  707-16     Citation Subset:  IM    
Western Infirmary General, G-3/4, Glasgow, G11 6NT, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects,  pharmacology,  therapeutic use*
B-Lymphocytes / cytology,  drug effects,  immunology
Down-Regulation / drug effects
Lupus Erythematosus, Systemic / drug therapy*
Off-Label Use*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Artificial organs: recent progress in metals and ceramics.
Next Document:  Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aur...